BioCentury | Sep 17, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-221 (miR-221); miR-222

...studies suggest inhibiting miR-221 and miR-222 could help treat dexamethasone-resistant MM. Levels of miR-221 and miR-222...
...lines, respectively. In a human dexamethasone-resistant MM cell line, dexamethasone and knockdown of miR-221 and miR-222...
...decreased cell viability and increased markers of apoptosis compared with dexamethasone and normal miR-221 and miR-222...
BioCentury | Feb 10, 2014
Company News

Regulus, Sanofi deal

...Sanofi an exclusive option to develop and commercialize Regulus' preclinical program targeting microRNA-221 (miR-221) and miR-222...
BioCentury | Nov 10, 2011
Distillery Therapeutics

Indication: Cancer

...status Publication and contact information Cancer Breast cancer MicroRNA-222 (miR-222); miR-181b Studies in mice suggest inhibiting miR-222...
...help treat tamoxifen-resistant breast cancer. In tamoxifen-treated xenograft mice with drug-resistant breast cancer, injection of anti-miR-222...
...include exploring oligonucleotide delivery systems and identifying other pharmacological agents that could lower miR-181b or miR-222...
BioCentury | Jan 7, 2010
Distillery Therapeutics

Indication: Cancer

...Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lung cancer; liver cancer MicroRNA-221 (miR-221); miR-222...
...tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) Studies in cell culture suggest that inhibiting miR-221 and miR-222...
...In human non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) cells, increased miR-221 and miR-222...
Items per page:
1 - 4 of 4